Specifically, we reveal that increasing GSK3β activity, by manipulating its upstream regulators AKT and PP2A, reduces NOTCH1 signaling and CLL cell survival (Fig. 8). This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.